Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. Alessandro Maselli, President…
Nura Bio, Inc., a clinical-stage, biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, announced the appointments of Lahar Mehta, M.D. as Chief Medical Officer, and Scott Greenberg as Chief Business Officer. Dr. Mehta and Mr. Greenberg …
AbbVie announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 201…
LEO Pharma announces the appointment of a new Executive Vice President, North America. Robert Spurr will join the Global Leadership Team and serve as CEO and President, LEO Pharma Inc. United States. Robert succeeds Brian Hilberdink, who will be leaving LEO Pharma to pursue an external opportunity in a large pharmaceu…
Baxter International Inc. announced that José (Joe) E. Almeida, chair, president and chief executive officer (CEO), will retire from his executive roles with the company, effective immediately. He will serve in an advisory capacity through Oct. 31, 2025. The Baxter Board of Directors has appointed lead independent di…
VentureLAB is proud to announce the appointment of Nima Khadem Mohtaram as Head of MedTech Initiatives, a pivotal step in advancing its mission of powering hardtech founders to build and scale globally competitive ventures that advance Canada’s knowledge-based economy. This appointment also reinforces ventureLAB’s thr…
Takeda announced that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the company in June 2026.…
Lyndra Therapeutics, a clinical-stage biopharmaceutical company pioneering long-acting oral therapies, announced the Board of Directors has appointed Adam Sayer as President and Chief Executive Officer effective immediately. He will also serve on the company’s Board of Directors. Sayer was most recently Chief Transfo…
Page 16 of 16